NCT01752153View on ClinicalTrials.gov

Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Immune Abnormalities
Interventions
DRUG

Desferrioxamine, Legalon® (Silymarin)

Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)

DRUG

Silymarin (Legalon)

Trial Locations (1)

Unknown

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz

All Listed Sponsors
lead

Shiraz University of Medical Sciences

OTHER

NCT01752153 - Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major | Biotech Hunter | Biotech Hunter